Latest Platform Technology News

Streamplay Studio Limited reports its second consecutive cash-flow positive quarter, driven by strong game launches and platform growth across Tier 1 markets and emerging regions.

Stakk Limited has reported explosive growth in its SaaS revenue and client base in 2025, positioning itself as a leading embedded finance infrastructure provider. The company’s ARR surged over 300%, driven by major US fintech partnerships and a strategic pivot to a modular SaaS model.

Starpharma has secured a $5.5 million upfront payment from Genentech as part of a new collaboration to develop dendrimer-drug conjugates targeting cancer therapies. The partnership includes potential milestone payments exceeding half a billion dollars and tiered royalties.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

Australian Finance Group Ltd (AFG) reported a robust 21% increase in net profit for FY25, driven by strategic broker network expansion and technology investments, while setting ambitious growth goals through FY29.

Vinyl Group Ltd reports a striking 190% revenue surge in FY25 and a record Q1 FY26, setting sights on its first EBITDA-positive quarter by mid-2026.

PlaySide Studios has extended its development contract with Meta Platforms for Horizon Worlds by 12 months, reinforcing its revenue outlook through 2026.

Streamplay Studio Limited reported a remarkable 201% surge in operating revenue for FY25, driven by its strategic acquisition of Noodlecake Studios and expansion into new markets. Despite a wider operating loss, the company achieved positive cash flow and profitability in the final quarter, signaling a promising turnaround.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Urbanise.com Ltd reported a solid FY2025 with 12.7% growth in Annual Recurring Revenue, underpinned by a strategic partnership with National Australia Bank that includes a 15% equity stake. The company strengthened its cash position and is poised for a new integrated payments solution launch in 2026.